Impact of SOFT/TEXT in Premenopausal Breast Cancer

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

Those aged 18 to 40 years with invasive, HER2-positive breast cancer showed a survival benefit from upfront surgery over neoadjuvant chemotherapy.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

April 15th 2024

PET Imaging Agent Earns FDA Fast Track Designation in Recurrent Glioma

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Finding Ways to Break the Mold in GU Oncology

TLX101 is currently under assessment as a treatment for glioma in the IPAX-2 and IPAX-Linz studies.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

April 8th 2024

Survival Outcomes Improve With TIL Presence in TNBC

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

An increased TIL count in the breast tissue was associated with improved distant recurrence-free survival in patients with triple-negative breast cancer.

Increased Thyroid Cancer Risk Not Observed After Use of GLP1 Receptor Agonist

An increased TIL count in the breast tissue was associated with improved distant recurrence-free survival in patients with triple-negative breast cancer.

Younger Patients With HER2+ Breast Cancer May Benefit from Surgery First

Patients who are predisposed to medullary thyroid cancer should be advised against the use of GLP1 agents.

Related Content

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

Those aged 18 to 40 years with invasive, HER2-positive breast cancer showed a survival benefit from upfront surgery over neoadjuvant chemotherapy.

April 15th 2024

PET Imaging Agent Earns FDA Fast Track Designation in Recurrent Glioma

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Finding Ways to Break the Mold in GU Oncology

TLX101 is currently under assessment as a treatment for glioma in the IPAX-2 and IPAX-Linz studies.

April 8th 2024

Survival Outcomes Improve With TIL Presence in TNBC

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Increased Thyroid Cancer Risk Not Observed After Use of GLP1 Receptor Agonist

An increased TIL count in the breast tissue was associated with improved distant recurrence-free survival in patients with triple-negative breast cancer.